Synthesize Bio is a technology company.
Synthesize Bio has raised $10.0M across 1 funding round.
Synthesize Bio has raised $10.0M in total across 1 funding round.
Synthesize Bio is an AI-driven genomics platform that generates and analyzes gene expression data to accelerate biomedical discovery and early-stage research by letting scientists create, validate, and export experimental datasets programmatically or through cloud notebooks[2][1].
High-Level Overview
Synthesize Bio builds a “Generative Genomics Engine” — a suite of generative AI models and data tooling that can predict outcomes of gene-expression experiments and create harmonized synthetic datasets for analysis and hypothesis testing[2][1]. The product is aimed at life‑science researchers, computational biologists, and drug‑development teams that need large, well‑annotated expression datasets for target discovery, experiment planning, and early translational work[2][1]. By enabling dataset generation, rapid QC/analysis, and easy export, the company addresses the slow, costly, and often noisy process of generating experimental expression data and reduces time‑to‑insight in preclinical research[2][1]. Early traction includes a public launch with seed financing reported at $10M and industry commentary positioning Synthesize Bio at the forefront of “generative genomics”[4][3].
Origin Story
Synthesize Bio was founded by a multidisciplinary team combining leaders in computational biology, AI, and product/engineering; the company highlights co‑CEOs and scientific/engineering leads with backgrounds in functional genomics, cancer biology, RNA therapeutics, and software engineering[1]. The idea emerged from the intersection of deep expertise in functional genomics and advances in generative AI — applying generative modeling to predict and synthesize gene expression data so researchers can test hypotheses faster without running every wet‑lab experiment[1][2]. Early milestones include product availability via cloud notebooks and an API, SOC 2 security certification, and seed funding that supported public launch and positioning by strategic investors and ecosystem commentators[2][1][4].
Core Differentiators
Role in the Broader Tech Landscape
Synthesize Bio sits at the convergence of two major trends: the rise of generative AI and the growing need for high‑quality, large‑scale biological datasets for discovery and translational research[3][2]. Timing matters because experimental biology remains costly and slow, while modern ML models require large, diverse training and validation datasets — generative genomics can augment scarce experimental data and enable more robust in‑silico hypothesis testing[3][2]. Market forces favor approaches that reduce early‑stage R&D cost and accelerate go/no‑go decisions in drug discovery; if synthetic datasets can meaningfully predict experimental outcomes, they can alter how preclinical programs are prioritized and designed[3][4]. The company also influences the ecosystem by providing infrastructure and tooling that could be embedded into academic, biotech, and pharma data‑science stacks, and by helping define standards and best practices around synthetic biological data use and validation[2][3].
Quick Take & Future Outlook
Synthesize Bio’s near‑term path will likely focus on (1) improving biological fidelity and validation of generated datasets against real experiments, (2) expanding dataset coverage and model capabilities across tissues, perturbations, and assay types, and (3) deepening integrations with pharma and biotech workflows via APIs and compliance features[2][4]. Key trends that will shape its journey include community and regulatory acceptance of synthetic biological data for decision making, continued advances in multimodal generative models, and demand from pharmaceutical R&D for tools that de‑risk early programs[3][4]. If the company can demonstrate reproducible predictive value and robust external validation, it could become a standard data layer in computational drug discovery; conversely, adoption will depend on transparent benchmarking and clear guidelines for responsible use of synthetic genomic data[4][2].
Overall, Synthesize Bio positions itself as a catalytic platform for accelerating genomics‑driven discovery by making experiment‑scale gene‑expression data generable, analyzable, and integrable into researchers’ pipelines — a timely play where AI meets practical needs in life‑science R&D[2][1][3].
Synthesize Bio has raised $10.0M in total across 1 funding round.
Synthesize Bio's investors include Goat Capital, Greylock, Hanabi Capital, Madrona Ventures, Menlo Ventures, Ann Bordetsky.
Synthesize Bio has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $10.0M Seed | Goat Capital, Greylock, Hanabi Capital, Madrona Ventures, Menlo Ventures, Ann Bordetsky |